Literature DB >> 19701821

Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.

T B Brismar1, N Dahlstrom, N Edsborg, A Persson, O Smedby, N Albiin.   

Abstract

BACKGROUND: A thorough understanding of magnetic resonance (MR) contrast media dynamics makes it possible to choose the optimal contrast media for each investigation. Differences in visualizing hepatobiliary function between Gd-BOPTA and Gd-EOB-DTPA have previously been demonstrated, but less has been published regarding differences in liver vessel visualization.
PURPOSE: To compare the liver vessel and liver parenchymal enhancement dynamics of Gd-BOPTA (MultiHance) and Gd-EOB-DTPA (Primovist).
MATERIAL AND METHODS: The signal intensity of the liver parenchyma, the common hepatic artery, the middle hepatic vein, and a segmental branch of the right portal vein was obtained in 10 healthy volunteers before contrast media administration, during arterial and portal venous phases, and 10, 20, 30, 40, and 130 min after intravenous contrast medium injection, but, due to scanner limitations, not during the hepatic venous phase. The doses of contrast media were 0.1 mmol/kg for Gd-BOPTA and 0.025 mmol/kg for Gd-EOB-DTPA.
RESULTS: Maximum enhancement of liver parenchyma was observed from the portal venous phase until 130 min after Gd-BOPTA administration and from 10 min to 40 min after Gd-EOB-DTPA. There was no difference in maximum enhancement of liver parenchyma between the two contrast media. When using Gd-BOPTA, the vascular contrast enhancement was still apparent 40 min after injection, but had vanished 10 min after Gd-EOB-DTPA injection. The maximum difference in signal intensity between the vessels and the liver parenchyma was significantly greater with Gd-BOPTA than with Gd-EOB-DTPA (P<0.0001).
CONCLUSION: At the dosage used in this study, Gd-BOPTA yields higher maximum enhancement of the hepatic artery, portal vein, and middle hepatic vein during the arterial and the portal venous phase and during the delayed phases than Gd-EOB-DTPA does, whereas there is no difference in liver parenchymal enhancement between the two contrast agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701821     DOI: 10.1080/02841850903055603

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  23 in total

1.  High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

Authors:  Scott K Nagle; Reed F Busse; Anja C Brau; Jean H Brittain; Alex Frydrychowicz; Yuji Iwadate; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-05-30       Impact factor: 4.813

2.  Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid.

Authors:  Alex Frydrychowicz; Scott K Nagle; Sharon L D'Souza; Karl K Vigen; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2011-07-12       Impact factor: 4.813

3.  Modified CAIPIRINHA-VIBE without view-sharing on gadoxetic acid-enhanced multi-arterial phase MR imaging for diagnosing hepatocellular carcinoma: comparison with the CAIPIRINHA-Dixon-TWIST-VIBE.

Authors:  Seung Baek Hong; Nam Kyung Lee; Suk Kim; Hyeong Il Seo; Hyun Sung Kim; Dong Uk Kim; Tae Un Kim; Hwa Seong Ryu
Journal:  Eur Radiol       Date:  2019-04-16       Impact factor: 5.315

4.  Radial volumetric imaging breath-hold examination (VIBE) with k-space weighted image contrast (KWIC) for dynamic gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI of the liver: advantages over Cartesian VIBE in the arterial phase.

Authors:  Yasunari Fujinaga; Ayumi Ohya; Hirokazu Tokoro; Akira Yamada; Kazuhiko Ueda; Hitoshi Ueda; Yoshihiro Kitou; Yasuo Adachi; Aya Shiobara; Naomichi Tamaru; Marcel D Nickel; Katsuya Maruyama; Masumi Kadoya
Journal:  Eur Radiol       Date:  2014-03-15       Impact factor: 5.315

5.  An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging.

Authors:  Utaroh Motosugi; Peter Bannas; Candice A Bookwalter; Katsuhiro Sano; Scott B Reeder
Journal:  Radiology       Date:  2015-10-16       Impact factor: 11.105

6.  Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.

Authors:  Jean-Nicolas Vauthey; Elijah Dixon; Eddie K Abdalla; W Scott Helton; Timothy M Pawlik; Bachir Taouli; Antoine Brouquet; Reid B Adams
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 7.  Magnetic Resonanance Imaging of the Liver (Including Biliary Contrast Agents)-Part 2: Protocols for Liver Magnetic Resonanance Imaging and Characterization of Common Focal Liver Lesions.

Authors:  Andrea Agostini; Moritz F Kircher; Richard K G Do; Alessandra Borgheresi; Serena Monti; Andrea Giovagnoni; Lorenzo Mannelli
Journal:  Semin Roentgenol       Date:  2016-05-30       Impact factor: 0.800

Review 8.  The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Kyung Won Kim; Gene Young Kim; Yong Moon Shin; Pyo Nyun Kim; Seong Ho Park
Journal:  Eur Radiol       Date:  2014-12-24       Impact factor: 5.315

Review 9.  Hepatobiliary MR imaging with gadolinium-based contrast agents.

Authors:  Alex Frydrychowicz; Meghan G Lubner; Jeffrey J Brown; Elmar M Merkle; Scott K Nagle; Neil M Rofsky; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-03       Impact factor: 4.813

10.  Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.

Authors:  Claudia Khouri Chalouhi; Federica Vernuccio; Francesca Rini; Piergiorgio Duca; Bruno Tuscano; Giuseppe Brancatelli; Angelo Vanzulli
Journal:  Eur Radiol       Date:  2018-12-13       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.